Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Receivables: 2022-2024

Historic Receivables for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to $75,000.

  • Corvus Pharmaceuticals' Receivables fell 77.14% to $32,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $272,000, marking a year-over-year decrease of 13.38%. This contributed to the annual value of $75,000 for FY2024, which is 44.23% up from last year.
  • Per Corvus Pharmaceuticals' latest filing, its Receivables stood at $75,000 for FY2024, which was up 44.23% from $52,000 recorded in FY2023.
  • Corvus Pharmaceuticals' 5-year Receivables high stood at $1.2 million for FY2022, and its period low was $52,000 during FY2023.
  • For the 3-year period, Corvus Pharmaceuticals' Receivables averaged around $434,333, with its median value being $75,000 (2024).
  • Per our database at Business Quant, Corvus Pharmaceuticals' Receivables tumbled by 95.58% in 2023 and then skyrocketed by 44.23% in 2024.
  • Over the past 3 years, Corvus Pharmaceuticals' Receivables (Yearly) stood at $1.2 million in 2022, then plummeted by 95.58% to $52,000 in 2023, then soared by 44.23% to $75,000 in 2024.